Sialic Acid-Fibronectin-negative and Vimentin-positive Breast Cancers Have Poor Prognoses due to Epithelial-Mesenchymal Transition
Anticancer Research · 2025
DOI: 10.21873/anticanres.17543 ↗At a glance
Journal article in Anticancer Research, 2025. Written by Hiroshi Takeyama and 9 co-authors. Institution: Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan; takeyama@jikei.ac.jp. Major MEDLINE topics: Epithelial-Mesenchymal Transition, Breast Neoplasms, Vimentin, Fibronectins.
Abstract (original language)
Ebda abstract disponibbli.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan; takeyama@jikei.ac.jp.
- Institute of DNA Sciences, Yokohama, Japan.
- Department of Digestive Surgery, Jikei University School of Medicine, Tokyo, Japan.
- Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan.
Cite
APA
Takeyama, H., Manome, Y., Koyama, M., Yoshii, Y., Taguchi, E., Fuke, A., Yamashita, T., Fuse, Y., Fushimi, A., & Nogi, H. (2025). Sialic Acid-Fibronectin-negative and Vimentin-positive Breast Cancers Have Poor Prognoses due to Epithelial-Mesenchymal Transition. Anticancer Research. https://doi.org/10.21873/anticanres.17543
Vancouver
Takeyama H, Manome Y, Koyama M, Yoshii Y, Taguchi E, Fuke A, et al. Sialic Acid-Fibronectin-negative and Vimentin-positive Breast Cancers Have Poor Prognoses due to Epithelial-Mesenchymal Transition. Anticancer Research. 2025. doi:10.21873/anticanres.17543
BibTeX
@article{Takeyama2025,
author = {Takeyama, Hiroshi and Manome, Yoshinobu and Koyama, Muneyuki and Yoshii, Yukiko and Taguchi, Eriko and Fuke, Azusa and Yamashita, Takaaki and Fuse, Yoshinobu and Fushimi, Atushi and Nogi, Hiroko},
title = {Sialic Acid-Fibronectin-negative and Vimentin-positive Breast Cancers Have Poor Prognoses due to Epithelial-Mesenchymal Transition},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17543}
}
EUVIMED